Urocortins: take them to heart

Area of Science:

• Cardiovascular Biology
• Neuroendocrinology
• Cellular Stress Response

Background:

• Urocortins, related to corticotropin-releasing hormone (CRH), are involved in stress coping behaviors and are expressed in the heart.
• Cardiac CRH-R2 receptors, which bind urocortins, are also present in the heart, suggesting a local role.

Purpose of the Study:

• To investigate the cardioprotective effects of urocortins against ischemia/reperfusion (I/R) injury.
• To explore the mechanisms underlying urocortin-mediated cardioprotection.
• To assess the potential clinical utility of urocortins in cardiac conditions.

Main Methods:

• In vitro, ex vivo, and in vivo models of I/R injury.
• Isolated perfused heart studies.
• Measurement of cell death, high energy phosphates, and gene expression (Kir6.1 K(ATP) channels, HSP90).
• Ovine model of heart failure.

Main Results:

• Endogenous cardiac urocortin expression increases with I/R injury.
• Exogenous urocortins reduce cell death and improve hemodynamic recovery in I/R injury.
• Urocortin treatment partially preserves high-energy phosphates and upregulates Kir6.1 K(ATP) channels and HSP90.
• Early data suggests beneficial hemodynamic effects in heart failure models.

Conclusions:

• Urocortins exhibit significant cardioprotective effects against I/R injury through multiple mechanisms.
• Urocortins demonstrate potential as therapeutic agents for I/R injury and possibly heart failure.
• Further clinical investigation into urocortins for cardiac conditions is warranted.